Zhaoke Ophthalmology (9FX) Stock Overview
Operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
9FX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Zhaoke Ophthalmology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.27 |
| 52 Week High | HK$0.46 |
| 52 Week Low | HK$0.25 |
| Beta | 1.07 |
| 1 Month Change | 3.03% |
| 3 Month Change | -13.38% |
| 1 Year Change | -9.93% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 37.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9FX | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -6.2% | -2.0% | 0.1% |
| 1Y | -9.9% | 36.5% | -0.5% |
Return vs Industry: 9FX underperformed the German Pharmaceuticals industry which returned 36.5% over the past year.
Return vs Market: 9FX underperformed the German Market which returned -0.5% over the past year.
Price Volatility
| 9FX volatility | |
|---|---|
| 9FX Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 9FX has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 9FX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 276 | Benjamin Li | www.zkoph.com |
Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the treatment of allergic conjunctivitis. It also engages in the development of NVK-002, an ophthalmic solution to control or slow myopia progression in children and adolescents; BRIMOCHOL PF and Carbachol PF pupil-modulating eye drops to correct for the loss of near vision associated with presbyopia; TAB014, a clinical-stage bevacizumab-based antibody indicated for wAMD; and PAN-90806 a drug indicated in the treatment of wAMD and DME.
Zhaoke Ophthalmology Limited Fundamentals Summary
| 9FX fundamental statistics | |
|---|---|
| Market cap | €161.77m |
| Earnings (TTM) | -€27.13m |
| Revenue (TTM) | €4.15m |
Is 9FX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9FX income statement (TTM) | |
|---|---|
| Revenue | CN¥31.97m |
| Cost of Revenue | CN¥15.92m |
| Gross Profit | CN¥16.05m |
| Other Expenses | CN¥225.04m |
| Earnings | -CN¥208.98m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 50.21% |
| Net Profit Margin | -653.60% |
| Debt/Equity Ratio | 17.2% |
How did 9FX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 00:44 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zhaoke Ophthalmology Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |
| Yue-Kwong Lui | Jefferies LLC |